These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 11968154)

  • 1. Pharmacokinetics of rhuMAb CD18, a recombinant humanised monoclonal antibody fragment to CD18, in normal healthy human volunteers.
    Allison DE; Gourlay SG; Koren E; Miller RM; Fox JA
    BioDrugs; 2002; 16(1):63-70. PubMed ID: 11968154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant humanized monoclonal antibody against CD18 (rhuMAb CD18) in traumatic hemorrhagic shock: results of a phase II clinical trial. Traumatic Shock Group.
    Rhee P; Morris J; Durham R; Hauser C; Cipolle M; Wilson R; Luchette F; McSwain N; Miller R
    J Trauma; 2000 Oct; 49(4):611-9; discussion 619-20. PubMed ID: 11038077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) study.
    Baran KW; Nguyen M; McKendall GR; Lambrew CT; Dykstra G; Palmeri ST; Gibbons RJ; Borzak S; Sobel BE; Gourlay SG; Rundle AC; Gibson CM; Barron HV;
    Circulation; 2001 Dec; 104(23):2778-83. PubMed ID: 11733394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
    Zhuang Y; Calderon C; Marciniak SJ; Bouman-Thio E; Szapary P; Yang TY; Schantz A; Davis HM; Zhou H; Xu Z
    Eur J Clin Pharmacol; 2016 Nov; 72(11):1303-1310. PubMed ID: 27515978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
    Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
    MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
    Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
    Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group.
    Milgrom H; Fick RB; Su JQ; Reimann JD; Bush RK; Watrous ML; Metzger WJ
    N Engl J Med; 1999 Dec; 341(26):1966-73. PubMed ID: 10607813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, Pharmacokinetics and Pharmacodynamics of TNHH, a Novel Targeted Neutrophil-Inhibitory Hirulog Hybrid Glycoprotein, in Healthy Volunteers.
    Gou ZP; Song ZH; Chen XG; Hu XC; Wang Y; Fan K; Cai YM; Zheng L
    CNS Drugs; 2019 Jun; 33(6):605-614. PubMed ID: 31093952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis.
    Casale TB; Bernstein IL; Busse WW; LaForce CF; Tinkelman DG; Stoltz RR; Dockhorn RJ; Reimann J; Su JQ; Fick RB; Adelman DC
    J Allergy Clin Immunol; 1997 Jul; 100(1):110-21. PubMed ID: 9257795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.
    Gordon MS; Margolin K; Talpaz M; Sledge GW; Holmgren E; Benjamin R; Stalter S; Shak S; Adelman D
    J Clin Oncol; 2001 Feb; 19(3):843-50. PubMed ID: 11157038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
    Gaudinski MR; Coates EE; Houser KV; Chen GL; Yamshchikov G; Saunders JG; Holman LA; Gordon I; Plummer S; Hendel CS; Conan-Cibotti M; Lorenzo MG; Sitar S; Carlton K; Laurencot C; Bailer RT; Narpala S; McDermott AB; Namboodiri AM; Pandey JP; Schwartz RM; Hu Z; Koup RA; Capparelli E; Graham BS; Mascola JR; Ledgerwood JE;
    PLoS Med; 2018 Jan; 15(1):e1002493. PubMed ID: 29364886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, potential efficacy, and pharmacokinetics of specific polyclonal immunoglobulin F(ab')₂ fragments against avian influenza A (H5N1) in healthy volunteers: a single-centre, randomised, double-blind, placebo-controlled, phase 1 study.
    Bal C; Herbreteau CH; Buchy P; Rith S; Zaid M; Kristanto W; Han V; Reynaud C; Granjard P; Lépine B; Durand C; Tambyah PA
    Lancet Infect Dis; 2015 Mar; 15(3):285-92. PubMed ID: 25662592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
    Mordenti J; Cuthbertson RA; Ferrara N; Thomsen K; Berleau L; Licko V; Allen PC; Valverde CR; Meng YG; Fei DT; Fourre KM; Ryan AM
    Toxicol Pathol; 1999; 27(5):536-44. PubMed ID: 10528633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postischemic treatment (2-4 h) with anti-CD11b and anti-CD18 monoclonal antibodies are neuroprotective after transient (2 h) focal cerebral ischemia in the rat.
    Zhang ZG; Chopp M; Tang WX; Jiang N; Zhang RL
    Brain Res; 1995 Nov; 698(1-2):79-85. PubMed ID: 8581506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
    Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
    Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraocular pharmacokinetics and safety of a humanized monoclonal antibody in rabbits after intravitreal administration of a solution or a PLGA microsphere formulation.
    Mordenti J; Thomsen K; Licko V; Berleau L; Kahn JW; Cuthbertson RA; Duenas ET; Ryan AM; Schofield C; Berger TW; Meng YG; Cleland J
    Toxicol Sci; 1999 Nov; 52(1):101-6. PubMed ID: 10568703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new fully human recombinant FSH (follitropin epsilon): two phase I randomized placebo and comparator-controlled pharmacokinetic and pharmacodynamic trials.
    Abd-Elaziz K; Duijkers I; Stöckl L; Dietrich B; Klipping C; Eckert K; Goletz S
    Hum Reprod; 2017 Aug; 32(8):1639-1647. PubMed ID: 28591833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and Tolerability of Obiltoxaximab: A Report of 5 Healthy Volunteer Studies.
    Nagy CF; Leach TS; Hoffman JH; Czech A; Carpenter SE; Guttendorf R
    Clin Ther; 2016 Sep; 38(9):2083-2097.e7. PubMed ID: 27568215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.